Rare disease Archives

orphazyme niemann pick type c disease rare metabolic disease molecules

News and Trends 30 Jan 2019

Danish Biotech’s Drug for Rare Metabolic Disease Aces Clinical Trial

A drug, developed by the Danish biotech Orphazyme for a rare metabolic disease, has shown promising results in a phase II/III trial, reducing the disease’s progression by 74%. The 50 patients recruited into the trial suffered from Niemann-Pick disease type C, a metabolic disease in which proteins crucial for storing fat molecules such as cholesterol […]

January 30, 2019 - 3 minutesmins - By Jonathan Smith

amryt skin gene therapy epidermolysis bullosa

News and Trends 8 Jan 2019

Topical Gene Therapy Shows Early Promise for Inherited Skin Disease

A gene therapy applied to the skin, developed by UK company Amryt Pharma, showed positive preclinical results for the treatment of a rare genetic skin disease. The disease, called recessive dystrophic epidermolysis bullosa (RDEB), is one of a group of diseases in which sufferers have mutations in proteins vital to the integrity of the […]

January 8, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 7 Dec 2018

Orchard’s Gene Therapy for Rare Immune Disease Works for Over a Year

A single dose of a gene therapy developed by Orchard Therapeutics can restore immune function for at least a year in patients with X-linked chronic granulomatous disease (X-CGD). The gene therapy was trialed in patients between the ages of 2 and 27 with the rare disease, which is caused by a rare genetic mutation that […]

December 7, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

Interview 28 Nov 2018

Navigating the Rare Disease Space: Insights from a Danish CEO

Developing drugs for rare diseases is a tough nut for biotech companies to crack. Labiotech’s Helen Albert interviewed the CEO of the Danish company Orphazyme, Anders Hinsby, at the recent BIO-Europe conference in Copenhagen, who told her about the appeals and challenges of making it in the rare disease space. Traditionally, the low number of […]

November 28, 2018 - 5 minutesmins - By Jonathan Smith

More News! 22 Nov 2018

First Drug for Rare Inflammation Syndrome Approved by FDA

The FDA has approved the first drug for the treatment of a rare condition in which the body produces too many active immune cells, developed in a Swiss-Swedish partnership. The antibody drug, emapalumab, is approved to treat primary hemophagocytic lymphohistiocytosis. This condition is a rare, often fatal syndrome in which the immune system produces too […]

November 22, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 2 Nov 2018

Gut Bacteria Treatment Shows Promise for Rare Genetic Kidney Condition

The Swedish biotech Oxthera reported positive preliminary Phase II results using its gut bacteria treatment, Oxabact, in patients with a rare genetic condition that causes kidney failure. The results came from an interim analysis one year into a three-year trial, where Oxthera is testing its gut microbiome treatment on patients with primary hyperoxaluria type […]

November 2, 2018 - 2 minutesmins - By Jonathan Smith

More News! 16 Oct 2018

Drug Combination for Rare Genetic Nerve Disorder Nails Phase III

A treatment developed by French biotech Pharnext has become the first clinically proven therapy for a rare genetic disorder that affects the nervous system. In a Phase III trial, the treatment reduced the level of disability of patients with Charcot-Marie-Tooth disease, a condition that affects peripheral nerves. This disease causes problems with walking, running and […]

October 16, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 9 Oct 2018

Hormone Therapy for Inherited Hormonal Disorder Fails at Phase III

A European Phase III trial has become a major stress for British biotech Diurnal. Its specially designed hormone therapy was no better than conventional therapies in treating an inherited hormonal disorder. Congenital adrenal hyperplasia is a rare genetic condition where patients lack crucial enzymes for making hormones. The most common form lacks 21-hydroxylase, the enzyme […]

October 9, 2018 - 3 minutesmins - By Jonathan Smith

In Depth 9 Oct 2018

How to Capitalize on Opportunities in Underserved Disease Areas

Developing treatments for underserved diseases can be surprisingly profitable for biotechs, we asked the experts to tell us more about how best to exploit these areas. We hear a lot about cancer therapies or drugs to target heart disease in the press, but overall a lot less about treatments for more underserved areas. Often successful […]

October 9, 2018 - 9 minutesmins - By Helen Albert

News and Trends 26 Sep 2018

Spanish Biotech Raises €21.3M To Advance Rare Disease Pipeline

Rare genetic diseases in the central nervous system may be less of a headache in future, as Barcelona-based biotech Minoryx has raised €21.3M in series B fundraising to test its lead drug candidate against other rare neurological conditions. According to Philippe Monteyne, partner at investor Fund+, “it is the largest investment in biotech in Spain […]

September 26, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 3 Sep 2018

Oxford Biotech Raises €40M to Deliver Drugs to Hard-to-Reach Targets

Evox Therapeutics has raised £35.5M (€39.4M) in a Series B fundraising that has been backed, among others, by the venture arm of Google’s parent company. A spin-out from the University of Oxford and the Karolinska Institute, Evox Therapeutics has raised a large round that will fund the development of its drug delivery technology to […]

September 3, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 26 Jul 2018

AI Company Raises €8.6M to Find Drugs for Rare Diseases Faster and Cheaper Than Ever

Cambridge-based Healx has raised $10M (€8.6M) in a Series A round to scale up its AI technology, which could significantly reduce the time and cost of developing drugs for rare diseases. Backed, among other investors, by the founder of Abcam, Healx plans to use the fundraising to double its workforce from 15 to over 30 […]

July 26, 2018 - 4 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us